REQUEST A CONSULTATION

Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.
search-icon
News

COVID-19 Booster Shot Increases Protection Against Delta Variant Infection by 85%, Study Indicates

COVID-19 booster shot
A Sheba study suggests that higher levels of antibodies following a third dose of the Pfizer-BioNTech vaccine correlate with a reduced risk of COVID-19 infection.

According to a new Sheba Medical Center and Tel Aviv University study, published in the scientific journal Nature Immunology, the effectiveness of a third COVID-19 vaccine dose against PCR-confirmed infection, regardless of symptoms, is 85.6% higher compared to two doses.

In order to analyze the effectiveness of the third vaccine dose, researchers administered the jab to 12,290 healthcare workers who were not previously infected with COVID-19 and had already received the first and second vaccine doses.
Results indicate that out of the the12,290 participants, 407 (3.3%) tested positive for COVID-19 on a PCR test.

Data gathered as part of the study demonstrated that while the increase in antibodies is relatively small at around 170%, a 600% increase in neutralizing antibodies, which bind pathogens and prevent them from spreading infection, was recorded in comparison to the second vaccine dose.

The study also found that the higher levels of antibodies following a third dose of the Pfizer-BioNTech vaccine correlate with a reduced risk of COVID-19 infection.

Related
virtual care
Nuvo Group and Sheba Develop AI-Powered Gestational Diabetes Management Platform
A groundbreaking gestational diabetes pilot was recently completed by the two organizations, deploying Nuvo's INVU platform at Sheba’s Beyond Virtual Hospital, simplifying care for pregnant…
Read More
pain treatment for pancreatic cancer
Breakthrough Study: Radiation Therapy Effective for Pain Management in Cancer Patients
Pancreatic cancer, the 12th most common cancer worldwide, is associated with pain in approximately 75% of patients at the time of diagnosis, and as much…
Read More
arc center
News Nov 30.
Real-Time Detection of Cancerous Biomarkers With Artificial Intelligence
Lung cancer is the most common cancer and accounts for 1.76 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all…
Read More